Pharma BD Deal Intelligence
FluMist was pitched as a $1B+ blockbuster nasal-flu vaccine; it took nearly two decades and CDC reversed course on its efficacy in children along the way — the deal never came close to justifying its $1.5-1.6B price tag.
Full analysis, sources & comparables →Form 425 details the stock-for-stock exchange offer of 1.075 MedImmune shares per Aviron share, presenting the FluMist-driven combination favorably to Aviron…
By acquiring Aviron, MedImmune gains rights to FluMist, an inhaled flu vaccine expected to gain regulatory approval in the second half of next year. FluMist…
MedImmune purchased Aviron in 2002, one year before FDA approval, and commercialized the product under the FluMist brand. The vaccine uses a cold-adapted…
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
MedImmune-Aviron stock-for-stock deal; 1.075 MedImmune shares per Aviron share at $47.41/share. Brought in FluMist intranasal flu vaccine. Closed 2002-01-10.
FluMist was pitched as a $1B+ blockbuster nasal-flu vaccine; it took nearly two decades and CDC reversed course on its efficacy in children along the way — the deal never came close to justifying its $1.5-1.6B price tag.
Assessment window: 15yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| MedImmune Inc. / Aviron (this deal) | 2001 | $1.5B | 36 |
| MedImmune Inc. / Aviron | 2002 | $1.5B | 28 |
| Abbott Laboratories / Knoll Pharmaceutical Company (BASF Pharma) | 2001 | $6.9B | 100 |
| Vertex Pharmaceuticals Incorporated / Aurora Biosciences Corporation | 2001 | $592M | 95 |
| Amgen Inc. / Immunex Corporation | 2001 | $16.0B | 91 |
| Swedish Orphan Biovitrum AB / Biovitrum | 2001 | $493M | 84 |
| Barr Laboratories Inc. / Duramed Pharmaceuticals Inc. | 2001 | $589M | 82 |
← Browse all deals · How we score deals
More: 2001 deals